Ownership history in JOHNSON & JOHNSON · 5 quarters on record
This page tracks every 13F SEC filing in which JOHNSON & JOHNSON reported a position in Lyell Immunopharma Inc. (LYEL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | UNCHANGED | 41,165 | — | 0% | 0.23% | $1.3M | $30.78 |
| 2025 Q3 | UNCHANGED | 41,165 | — | 0% | 0.13% | $669K | $16.24 |
| 2025 Q2 | REDUCED | 41,165 | -782,152 | -95.0% | 0.11% | $368K | $8.84 |
| 2025 Q1 | UNCHANGED | 823,317 | — | 0% | 0.13% | $443K | $10.76 |
As of 2025 Q4 — sorted by position size